一分钟看懂
这是一项关于结直肠癌的I 期 / II 期研究,登记的药物或干预包括HSK42360-Na Tablets;Cetuximab (EGFR inhibitor);mFOLFOX6 Regimen (Oxaliplatin/Leucovorin/5-FU);FOLFIRI Regimen (Irinotecan/Leucovorin/5-FU),当前状态为招募中。登记地点显示中国北京有研究中心记录。是否仍有名额以及是否值得进一步询问,需要向研究中心确认。
药物或干预
HSK42360-Na Tablets;Cetuximab (EGFR inhibitor);mFOLFOX6 Regimen (Oxaliplatin/Leucovorin/5-FU);FOLFIRI Regimen (Irinotecan/Leucovorin/5-FU) · I 期 / II 期
登记条件中文摘要
年龄范围:18岁及以上
登记的基本范围为不限性别,年龄18岁及以上;以下仅摘录8项专业入选条件,需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件,具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息,不代表此刻仍有名额;请向研究中心确认最新情况。
- Beijing Cancer Hospital · 北京
入选条件原文摘录
以下为摘录,请打开原始登记查看完整入排标准。
- 1. Age ≥18 years; voluntarily participate in this clinical trial, understand the study procedures, and have signed the informed consent form;
- 2. ECOG performance status 0-1;
- 3. Estimated survival time \>3 months;
- 4. Histologically or cytologically confirmed metastatic and unresectable colorectal adenocarcinoma. For Phase I, Phase II Cohort 1, and the safety lead-in period of Cohorts 2/3: previously received one or more systemic treatments for metastatic colorectal cancer, and failed standard treatment, or have no standard treatment option, or standard treatment is not applicable at this stage; for the subsequent expansion phase of Phase II Cohorts 2/3: no prior systemic treatment for metastatic colorectal cancer;
- 5. Genetic testing documentation (limited to PCR or NGS-based assays) must be provided prior to enrollment to demonstrate BRAF V600 mutation positivity;
- 6. Agree to provide tumor tissue and/or blood samples;
- 7. At least one measurable lesion according to RECIST 1.1 criteria;
- 8. Laboratory values meeting the following standards:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号:NCT07790510;登记信息更新于 2026-08-27;本站同步于 2026-11-21。